The stock's fall snapped a two-day winning streak.

Supported by world-class markets data from Dow Jones and FactSet, and partnering with Automated Insights, MarketWatch ...

Analysis of Biogen's stock performance in 2024, focusing on sales struggles, financial health, and valuation. Read more here.

Biogen (BIIB) stock slipped as Piper Sandler downgraded the company to neutral from overweight, citing challenges in Alzheimer's drug market. Read more here.

At the end of a second consecutive year during which the S&P 500 has risen more than 20%, two things investors need to remember are that time tends to smooth out performance and that the index is ...

In the Need to Know column on Christmas Eve, Barbara Kollmeyer shared insights from strategists at Evercore ISI led by Julian Emanuel, who considered year-end selling action and corporate financial ...

The fund owned 3,965 shares of the biotechnology company’s stock after selling 2,016 shares during the quarter. Sanctuary Advisors LLC’s holdings in Biogen were worth $769,000 as of its most ...

This often is a signal that the stock you are watching is weak. Waiting for a turn higher may be more intelligent than trying to catch a falling knife. In any case, new support levels are usually ...

BMO Capital Markets has recently reduced Biogen Inc (BIIB) stock to Market Perform rating, as announced on Today, according to Finviz. Earlier, on December 16, 2024, Stifel had reduced the stock from ...